medrogestone and Prostatic-Hyperplasia

Topics: Adrenergic alpha-Antagonists; Bromocriptine; Cyproterone; Gestonorone Caproate; Humans; Male; Medrogestone; Megestrol; Plant Extracts; Polyenes; Prostatic Hyperplasia; Spironolactone; Tamoxifen

Topics: Androgen Antagonists; Androgens; Animals; Castration; Cyproterone; Dogs; Drug Synergism; Estrogens; Hormones; Humans; Male; Medrogestone; Middle Aged; Polyenes; Progestins; Prostate; Prostatic Hyperplasia; Species Specificity; Spironolactone

The conversion of carbon-14-testosterone (T) to 5alpha-dihydrotestosterone (DHT) and androstanediol (A-diol) was studied in vitro using a crude homogenate of prostate from patients with benign prostatic hypertrophy. Under standard conditions, the mean conversion to DHT was 70 + or -1 (standare error, SE)% and to A-diol 14 + or -1 (SE)%. Addition of various antiandrogens and other substances decreased the T to DHT conversion to 0-55% and the T to A-diol to 0-10%. The most potent inhibitors were desoxycorticosterone and progesterone. Estradiol-17beta, cyproterone acetate, medrogestone, medroxyprogesterone acetate, estriol and 4'-nitro-3'trifluoromethylisobutyramilide were also effective inhibotors. To determine whether this effect might be significant in vivo, similar conversion studies were carried out on prostatic tissue obtained from 3 patients who had received oral medrogestone for 1-2 weeks. T to DHT was reduced to 12.2 + or -2.8 (SE)% and T to A-diol to 6.5 + or -1.0 (SE)%. The ability of such compounds to inhibit DHT formation represents 1 mode of action which may account at least in part for their efficacy in the treatment of benign prostatic hypertrophy.

Topics: Androgen Antagonists; Androstanes; Anilides; Carbon Radioisotopes; Cyproterone; Desoxycorticosterone; Dihydrotestosterone; Estradiol; Estriol; Humans; Hydrocarbons, Fluorinated; In Vitro Techniques; Male; Medrogestone; Medroxyprogesterone; Nitro Compounds; Progesterone; Progestins; Prostate; Prostatic Hyperplasia; Testosterone; Tritium